On January 17, 2019, the Federal Court of Appeal heard the Attorney General of Canada’s appeal from a judicial review that quashed a Board decision that it has jurisdiction over Galderma’s DIFFERIN (0.1% adapalene). Our report on the Federal Court decision, 2017 FC 1023, is found here. Innovative Medicines Canada intervened in the appeal. The Federal Court of Appeal reserved judgment.
- Checklist Checklist: Lawful processing of personal data under the GDPR (UK) Recently updated
- How-to guide How-to guide: What general counsel (GC) need to know about environmental, social and governance (ESG)
- How-to guide How-to guide: How to protect your company from violations of the United States Foreign Corrupt Practices Act (USA)